Kornimate/medical-research-clean huggingface dataset:
the emesh 1 feasibility study

Conditions: Atherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)

Summary: multi-center, dual cohort (randomized and single vessel) study designed to demonstrate feasibility, initial safety and performance of the kips bay medical, inc. esvs® mesh as an external vein support device for use over saphenous vein grafts during coronary artery bypass surgery. in the randomized cohort, each study subject will receive a svg without mesh (control) and a svg with the esvs mesh (treatment). in the single vessel cohort, each study subject will receive one svg with the esvs mesh.


Eligibility criteria:
inclusion criteria: * randomized cohort: requires cabg surgery with a svg to the right coronary artery (rca) system and the left circumflex artery (lcx) system with a ≥ 70% stenosis in each of the two systems. * single vessel cohort: requires cabg surgery with a svg to the rca system or the lcx system with a \> 70% stenosis in the system. * medial sternotomy with cardiopulmonary bypass (cpb) during surgery. * both saphenous vein graft length are adequate for planned intervention, vein outer diameter is between 3.6 mm and 7.0 mm and double wall thickness less than 1.4 mm. * agreement to post-procedure follow-up contact and testing (including follow-up coronary angiogram). exclusion criteria: * concomitant non-cabg cardiac procedure. * prior cardiac surgery (does not include percutaneous procedures). * cerebrovascular or transient ischemia attack within 30 days of the cabg procedure. * age \> 85 years. * left ventricular ejection fraction ≤ 35%. * creatinine \> 133 μmol/l (1.5 mg/dl) prior to cabg procedure or on chronic dialysis. * stemi within 7 days or total ck \> 2 times the upper limit of normal prior to the cabg procedure. * both enrolled grafts will feed non-viable myocardial territory. * diffuse atherosclerotic disease (\> 70%) distal to either of the enrolled target coronary arteries. * randomized cohort: by visual estimate, the target coronary artery diameter of both the right coronary system and left circumflex system must be within 1.5mm of each other. * planned endarterectomy of the target coronary artery.

Keywords: cabg svg nitinol mesh external saphenous vein graft support
low-dose protocol for computed tomography-guided lung biopsy

Conditions: Lung Cancer, Adenocarcinoma; Lung Inflammatory Pseudotumor

Summary: the purpose of this study is to compare the diagnostic accuracy and complication rate between low-dose computed tomography-guided and standard-dose computed tomography-guided lung biopsy.

with the comprehensive usage of computed tomography examination, patients are more and more aware of the radiation dose of computed tomography. concerns over the potential for radiation induced malignancies have increasingly been published in the scientific literature and reported in the popular press. the risk is highest for younger patients, who have more radiation-sensitive tissues and longer life expectancies than adults. recently, the united states food and drug administration announced an initiative to reduce unnecessary radiation exposure from medical imaging. at present, low-dose computed tomography protocol is widely used for the diagnosis of cardiovascular and cerebrovascular diseases. computed tomography-guided lung biopsy is widely used for diagnosis of lung nodules and masses. however, it requires repeating scanning to guide the needles, which inevitably increases the radiation dose. therefore, low-dose protocol was also used in the computed tomography-guided lung biopsy procedure. the purpose of this study is to compare the diagnostic accuracy and complication rate between low-dose computed tomography-guided and standard-dose computed tomography-guided lung biopsy.

Eligibility criteria:
inclusion criteria: * non-diagnostic lung lesions; solid lung lesions; lesion size ≥ 5mm. exclusion criteria: * the lesion which has been punctured previously; severe dysfunction in heart, lung and coagulation function.
the effects of pilates on functional capacity and blood glucose levels in adults with diabetes type 2

Conditions: Type 2 Diabetes Mellitus

Summary: the aim of this study is to investigate the effects of the pilates training on functional capacity among adults with type 2 diabetes the aim of this study is to investigate the effects of the pilates training on blood glucose response among adults with type 2 diabetes

a randomized control trial study of 3 month period will be arranged, at riphah international university faisalabad after the approval of synopsis. the convenience sampling technique will be selected for registration of patients. according to specified inclusion, exclusion criteria, patients will be chosen. calculation of sample size for the study tells need of both males and females (45 yrs-65 yrs) that will fulfill the certain criteria. the participants of group a will receive pilates exercise and standard care and participants of group b will receive a brisk walk on treadmill and standard care. the evaluation of patients will be done at baseline, at 6th week, 12th week and at follow up after one month of discontinuation of treatment. the patient's outcome will be measured by 6-minute walk test (distance), hemoglobin a1c level and blood glucose level and the recording of the patient's data will be at pre-treatment and post-treatment. the data of before treatment and after treatment will be compared at follow up after one month of discontinuation of treatment. for each patient informed consent will be taken. through statistical package of social sciences 20 software, data entry and analysis will be done

Eligibility criteria:
inclusion criteria: * diabetic patient both male and female with diagnosed with type ii diabetes * 45-65 years old * lack of psychic disease, dementia and mental retardation exclusion criteria: * ulcers in extremities * peripheral neuropathy * severe or decompensated heart disease * limited coronary heart disease * insulin therapy

Keywords: glycemic control hyperglycemia functionality pilates exercises
association of plasma ptx3 concentration and outcomes of stemi

Conditions: STEMI; Coronary; Ischemic

Summary: 335 of patients with stemi treated by primary pci were assayed for ptx3 measurement by elisa method. the angiographic and clinical outcomes were evaluated according to the ptx3 concentration.

335 of patients with stemi treated by primary pci were assayed for ptx3 measurement by elisa method using human ptx3 kit. blood was drawn at the emergency department before primary pci. the angiographic and clinical outcomes were evaluated and analyzed according to the ptx3 concentration. the angiographic outcome were thrombus grade on initial angiogram and final timi flow. the clinical outcome were ecg resolution after primary pci and all-cause death at 30 days. the plasma ptx3 concentration was then compared based on the outcomes.

Eligibility criteria:
inclusion criteria: * patients with acute stemi with symptom onset \<12 h undergoing primary pci exclusion criteria: * acute stemi patients who received fibrinolytic therapy
investigation of physical impairments in young adults

Conditions: Adult Children

Summary: physical inactivity is widespread among young adults due to different disasters like the covid-19 and earthquakes. on the other hand, it is unknown how physical activity level affects cough strength and balance in young adults. in current study, it was aimed to investigate both cough strength, physical activity and balance status in young adults and the relationship between these parameters.

participation in free time physical activities has various health benefits such as increasing academic success, improving quality of life. physical inactivity in university students has been triggered by disasters such as covid-19 and earthquakes that we have experienced. however, it is not yet known how physical inactivity and sedentary life affect cough strength and balance in these healthy young people. thus, this study aimed to explore the cough strength, physical activity and balance status and the correlations between these parameters in young adults.

Eligibility criteria:
inclusion criteria: * being 18 years or older, * volunteering to participate in the study * understanding and answering the questionnaire exclusion criteria: * having any physical or mental disability/disease and/or cognitive impairment that would prevent physical activities * being pregnant.

Keywords: adult balance cough covid-19 physical activity
non invasive detection of lung and breast cancer by odor signature

Conditions: Lung Cancer; Breast Cancer

Summary: the investigators have developed an early detection solution for lung and breast cancer. a system which can distinguish between different medical odors based on biosensors. our product is user-friendly noninvasive, nonradioactive and nontoxic to the patients. the technology enables a high level of sensitivity and provides users with a quick lab response and a simple yes or no answer. the aim of this study is to contribute and detect the patient at the earliest possible stage, in a noninvasive, nonradioactive and nontoxic way. exhaled breath and urine samples are a promising approach towards future possible lung and breast cancer screening method.

early detection of cancer can dramatically improve the survival chances. to date, there is no efficient diagnostic tool for detection of lung cancer in early stages. regarding breast cancer, the common screening tool us mammography, which suffer from low sensitivity and high false positive. thus, there is an urgent need for developing a screening tool for early stages lung and breast cancer. the sense of smell depends on the ability of specialized sensory cells of the nose to perceive volatile compounds (vocs). diseases such as infections and malignancies can be associated with changes in host metabolism, accompanied by production of different vocs, and thus a different odor. several studies have shown that different cancers secrete different vocs, thus produce different smell. we have developed a system which uses biosensors that can scent the vocs that lung and breast cancer cell produce, thus distinguish between healthy control and lung or breast cancer. these biosensors can detect low stages lung and breast cancer. patients will supply urine samples and exhaled breath samples using a kit that we will supply. the samples will be shipped to our lab, where they will be processed and the vocs will be separated from the head space of the samples. the biosensors will be exposed to the vocs samples and will report whether the specific sample id cancerous (lung or breast) or not. the data will be collected from all samples and statistical analysis will be calculated, in order to test the specificity and sensitivity of our biosensors to detect cancerous samples.

Eligibility criteria:
inclusion criteria: * diagnosed lung cancer patients * diagnosed breast cancer patients exclusion criteria: * cancer patients who were treated using chemotherapy * cancer patients who were treated using radiation * cancer patients who were treated using biological treatments * cancer patients who were treated with chemotherapy * cancer patients who were treated with any anti- cancer therapies * cancer patients who use drugs that affect the immune system

Keywords: lung cancer breast cancer biosensors volatile organic compounds odor urine sample exhaled breath samples
rct metformin for reduction of gestational diabetes mellitus effects

Conditions: Gestational Diabetes

Summary: the overall objective of the emerge trial is to determine whether metformin + usual care, compared to placebo + usual care (introduced at the time of initial diagnosis of gdm), reduces a) the need for insulin use, or hyperglycemia (primary outcome measure); b) excessive maternal weight gain; c) maternal and neonatal morbidities and, d) cost of treatment for women with gestational diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent 2. participants aged 18-50 3. pregnancy gestation up to 28 weeks (+ 6 days) confirmed by positive pregnancy test 4. singleton pregnancy as determined by scan 5. positive diagnosis of gestational diabetes mellitus on a oral glucose tolerance test (ogtt) according to the international association of the diabetes and pregnancy study groups (iadpsg) criteria if any one of the following are achieved: i) fasting glucose \>/= 5.1mmol/l and \ /=10mmol/l, or iii) 2 hour post glucose load of \>/=8.5 mmol/l and \<11.1mmo/l 6. resident in the locality and intending to deliver within the trial site exclusion criteria: 1. participants who have an established diagnosis of diabetes (type 1, type 2, monogenic or secondary) 2. participants with a fasting glucose \> 7mmol/l or a 2h value \> 11.1 mmol/l 3. multiple pregnancies (twins, triplets etc.) as determined by scan 4. known intolerance to metformin 5. known contraindication to the use of metformin which include: i) renal insufficiency (defined as serum creatinine of greater than 130 µmol/l or creatinine clearance \<60 ml/min), ii) moderate to severe liver dysfunction (aspartate aminotransferase (ast) and alanine aminotransferase (alt) greater than 3 times the upper limit of normal, iii) shock or sepsis, and iv) previous hypersensitivity to metformin 6. major congenital malformations or an abnormally deemed unsuitable for metformin by the site pi or attending consultant 7. known small for gestational age (small for gestational age (sga) refers to foetal growth less than the 10th percentile (rcog, 2014), or if foetal growth is deemed unsatisfactory by the treating obstetrician) 8. known gestational hypertension or pre-eclampsia or ruptured membranes 9. participants who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements 10. participants with significant gastrointestinal problems such as severe vomiting, crohn's disease or colitis which will inadvertently affect absorption of the study drug 11. participants with congestive heart failure or history of congestive heart failure 12. participants with serious mental illness which would affect adherence to study medication or compliance with study protocol in the opinion of the investigator 13. patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption

Keywords: gestational diabetes diabetes pregnancy
endoscopic anatomy of the breast fascia system

Conditions: Breast Disease; Anatomy

Summary: this study will focus on two key theories: the development theory of the breast fascia system and the reverse development theory. the research findings indicate that breast development generally follows a growth pattern from anterior to posterior, and from central to peripheral regions. however, an intriguing phenomenon contradicting this developmental process was discovered through endoscopic mastectomy, which has not been previously discussed. based on the aforementioned theoretical analysis, this study includes patients who underwent endoscopic and reduction mammaplasty in the department of breast surgery in the sixth affiliated hospital of sun yat-sen university. the investigators proposed the following research framework: firstly, comprehensively understanding the structure of the breast fascia and the sequence of breast development through endoscope and existing research; secondly, exploring the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty; lastly, proposing a reverse development theory for breast fascia based on these theories in order to provide standardized and procedural guidance for breast surgeons.


Eligibility criteria:
inclusion criteria: * breast cancer patients who need mastectomy and patients who need breast reduction during the study period. exclusion criteria: * breast conserving surgery
pattern of autoimmune hepatitis in children in sohag university hospital

Conditions: Autoimmune Hepatitis

Summary: autoimmune hepatitis (aih) is a progressive inflammatory liver disorder of unknown etiology. if left untreated, it progresses to liver cirrhosis and liver failure. diagnosis of aih relies on the exclusion of other causes of liver disease and the presence of positive clinical, biochemical, and histological criteria. aih has a very wide spectrum of clinical presentations ranging from being asymptomatic to an acute severe fulminant disease. it may be associated with other autoimmune disorders such as thyroiditis, type 1 diabetes, vitiligo, inflammatory bowel disease, or juvenile idiopathic arthritis. biochemical features of aih include elevation of serum alanine aminotransferase (alt), aspartate aminotransferase (ast), and immunoglobulin g (igg) in addition to autoantibodies. liver biopsy is recommended in any patient with suspected autoimmune hepatitis where interface hepatitis is the hallmark of the disease. immunosuppression is the mainstay of therapy in aih. prednisone is administered as the initial therapy either alone or in combination with azathioprine. liver transplantation is indicated in patients who develop fulminant hepatic failure that is unresponsive to corticosteroids and in patients who develop end-stage liver disease.


Eligibility criteria:
inclusion criteria: * age: under 18 years old. * both sex. * children suffering from manifestations of autoimmune hepatitis. children previously diagnosed with autoimmune hepatitis exclusion criteria: * patient infected with hepatitis b or c. * patient had autoimmune hepatitis after liver transplantation. * patients not respond to steroids and immunosuppressive therapy. other causes of acute and chronich hepatitis like wilson disease and metabolic liver diseases
response to cardiac resynchronization therapy in heart failure: role of arterial stiffness

Conditions: Arterial Stiffness

Summary: to determine if arterial stiffness as measured by non-invasive pulse wave velocity can predict the response to resynchronization therapy in heart failure.

the patients receiving crt are medically refractory, symptomatic, nyha class iii or iv disease and qrs duration of 130 m sec or greater, and a left ventricular ejection fraction of 30 percent or less. the pulse wave velocity between carotid and femoral (pwvcf) will be recorded in each subject at base line (before and after crt), at one month (after av delay optimization) and again at 6 months after crt. the arterial pulse wave is recorded at a proximal artery, such as the carotid artery, and as well as at a distal artery, such as the femoral artery. the superficial location of the carotid and femoral arteries means that their pulse waveforms are readily measured noninvasively using the m hz doppler probe, and between these two sites the pulse wave has to travel through most of the aorta. the time delay between the arrival of a predefined part of the pulse wave, such as the foot, at these 2 points is obtained by gating to the peak of the r-wave of the ecg. the distance traveled by the pulse wave is measured over the body surface and pwv is then calculated as distance/time (m/s). clinical evidence of response: either one or more of the following: 1) improvement in nyha functional classification, 2) improvement in 6 minute walking distance. 3) change in functional class, exercise tolerance while the heart is getting smaller on cxr. 4) stabilization of patient chf even without subjective improvement over 6 months (remaining class iii rather than progressive to class iv). imaging evidence of response: 1) increase in left ventricular ejection fraction. 2) reduction of mitral regurgitation. 3) reduction of lv volume signifying reverse remodeling.

Eligibility criteria:
inclusion criteria: * the patients receiving crt are medically refractory, symptomatic, nyha class iii or iv disease and qrs duration of 130 m sec or greater, and a left ventricular ejection fraction of 30 percent or less. * all individuals are carefully selected after appropriate clinical evaluation as determined by the treating physicians to exclude possible reversible causes of heart failure. exclusion criteria: * patients with permanent atrial fibrillation and non-palpable carotid and/or femoral pulses will be excluded due to technical limitations of the procedure used for the measurement of arterial stiffness.
metabolic changes as a diagnostic indicator for cancer

Conditions: Breast Cancer; Lung Cancer

Summary: this study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer. these analyses will be done by means of nuclear magnetic resonance (nmr) spectroscopy.


Eligibility criteria:
inclusion criteria: * diagnosis of breast or lung cancer (new lesion) exclusion criteria: * not fasted for at least 6 hours * plasma glucose concentration ≥ 200 mg/dl * intake of medication at the day of investigation * history/treatment of cancer in the previous 5 years

Keywords: nmr spectroscopy metabolic changes blood plasma biomarker cancer
determinants of oral corticosteroid responsiveness in wheezing asthmatic youth

Conditions: Asthma

Summary: the aim of the prospective cohort study is to: (1) document the magnitude of response to oral corticosteroids administered to children presenting to the emergency department with moderate or severe asthma and (2) quantify clinically available potential determinants of the response to corticosteroids, such as age, gender, triggers of the index exacerbation, environmental tobacco smoke (ets), gene polymorphisms, and their interactions.

the objective of the large multicentre cohort study is to quantify the response to oral corticosteroids in children aged 1 to 17 years presenting to the ed with a moderate or severe asthma exacerbation. the main outcome is hospital admission within 72 hours of the oral corticosteroid administration. secondary outcomes include the change in pediatric respiratory assessment measure (pram), length of active treatment and other markers of response to therapy in the ed as well as markers of recovery over the next 10 days.

Eligibility criteria:
inclusion criteria: * subject will be eligible if he/she: 1. is aged 1 to 17 years, 2. has not received any oral, im or iv corticosteroid within the last 5 days? 3. presents to the hospital emergency department with an acute episode of cough, wheezing and/or dyspnea? 4. has asthma as defined as one or more of the following 6 criteria: (i) prior diagnosis of asthma made by a physician; or (ii) prior documented episode of acute cough, wheezing and/or dyspnea with significant response to inhaled β2-agonists or to oral corticosteroids; or (iii) in a child aged \<2 years, 3 or more episodes of cough, wheezing and/or dyspnea, including the index visit; or (iv) previous lung function tests showing significant reversibility post-bronchodilation (≥12% fev1 or ≥25% rrs at 4 to 8 hz); or (v) a positive provocation test (pc20 ≤8 mg/ml or provocation dose (to increase rrs by 50% or more (pd50) ≤8 mg/ml), or (vi) the current episode diagnosed or suspected of asthma by the emergency physician? 5. have moderate or severe airway obstruction, defined as a paediatric respiratory asthma measure (pram) score \>3 at baseline, exclusion criteria: * patient will be excluded if : 1. he/she has another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic fibrosis); 2. there is a reasonable suspicion of bronchiolitis or foreign body aspiration; 3. he/she has a prior history of hypersensitivity to salbutamol, ipratropium bromide or oral prednisone/prednisolone; 4. he/she has a relative or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine in past 14 days, 5. there is confirmed or suspected pregnancy.

Keywords: asthma; children; cohort study; corticosteroids